menu
    • menu
    [{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Huadong Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Huadong Medicine"},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Insilico Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

    Menu

    Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Huadong Medicine and Insilico Medicine Enter Co-Development Partnership to Advance Oncology Drug Discovery by ...

                            Details : The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

                            China arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Immunogen

                            Deal Size : $305.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Sora...

                            Details : Partnership accelerates development path for Mirvetuximab in Greater China and expands Huadong Medicine’s oncology portfolio with innovative ADC.

                            Brand Name : IMGN853

                            Molecule Type : Large molecule

                            Upfront Cash : $40.0 million

                            October 19, 2020

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Immunogen

                            Deal Size : $305.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth